Across TCGA pan-cancer cohorts, TMEM120B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM120B data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM120B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM120B expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where TMEM120B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.715	1.000	<.001	39	view →
LSCC	DFS	Median	III,IV	0.564	0.988	.010	12	view →
HNSC	OS	Median	III,IV	0.937	1.000	.039	2	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.889	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TMEM120B tumor-vs-normal RNA expression · all TMEM120B data types